Senhwa Biosciences (ROCO:6492) FCF Margin %: -22,689.17% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6492 Senhwa Biosciences Inc ROCO:6492
70 GF Score
Price NT$43.70
GF Value NT$46.74
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Senhwa Biosciences FCF Margin %?

Senhwa Biosciences ROCO:6492 -1.35% 70 FCF Margin % is -22,689.17% as of Dec. 2025. GuruFocus rates ROCO:6492 with a GF Score™ of 70/100 and a GF Value™ of NT$46.74 (Fairly Valued). The stock has 2 warning signs investors should review. Among 950 Biotechnology companies, Senhwa Biosciences ranks worse than 95.68% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Senhwa Biosciences's Free Cash Flow for the three months ended in Dec. 2025 was NT$-54.45 Mil. Senhwa Biosciences's Revenue for the three months ended in Dec. 2025 was NT$0.24 Mil. Therefore, Senhwa Biosciences's FCF Margin % for the quarter that ended in Dec. 2025 was -22,689.17%.

As of today, Senhwa Biosciences's current FCF Yield % is -6.36%.

The historical rank and industry rank for Senhwa Biosciences's FCF Margin % or its related term are showing as below:

ROCO:6492' s FCF Margin % Range Over the Past 10 Years
Min: -173852.34   Med: -44257.86   Max: -23220.28
Current: -23220.28

During the past 13 years, the highest FCF Margin % of Senhwa Biosciences was -23220.28%. The lowest was -173852.34%. And the median was -44257.86%.

ROCO:6492's FCF Margin % is ranked worse than
95.68% of 950 companies
in the Biotechnology industry
Industry Median: -81.28 vs ROCO:6492: -23220.28

Senhwa Biosciences FCF Margin % Related Terms

Senhwa Biosciences FCF Margin % Historical Data

* Premium members only.

The historical data trend for Senhwa Biosciences's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Senhwa Biosciences FCF Margin % Chart

Senhwa Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -54,627.45 -40,034.00 -29,917.00 -29,617.30 -23,246.45

Senhwa Biosciences Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -25,800.00 -26,565.20 -23,256.00 -21,045.45 -22,689.17

ROCO:6492 vs VRTX, REGN, ALNY: FCF Margin % Comparison

For the Biotechnology subindustry, Senhwa Biosciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Senhwa Biosciences FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Senhwa Biosciences's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Senhwa Biosciences's FCF Margin % falls into.


ROCO:6492
70GF Score
Senhwa Biosciences Inc ROCO:6492
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Senhwa Biosciences FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Senhwa Biosciences's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-248.737/1.07
=-23,246.45 %

Senhwa Biosciences's FCF Margin for the quarter that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-54.454/0.24
=-22,689.17 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -22,689.17% mean?
Senhwa Biosciences (ROCO:6492) has a FCF Margin % of -22,689.17% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Senhwa Biosciences and its competitors. According to the industry distribution chart, Senhwa Biosciences ranks #909 out of 950 companies in the Biotechnology industry, placing it in the top 95.7%.
Is Senhwa Biosciences' FCF Margin % too high?
Senhwa Biosciences' current FCF Margin % is -22,689.17%. Based on the distribution chart, Senhwa Biosciences ranks #909 out of 950 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Senhwa Biosciences has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Senhwa Biosciences' FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Senhwa Biosciences ranks #909 out of 950 companies for FCF Margin %. This places Senhwa Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Senhwa Biosciences and its competitors. Senhwa Biosciences's current FCF Margin % is -22,689.17%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Senhwa Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Senhwa Biosciences (ROCO:6492) is currently considered Fairly Valued. The stock's GF Value™ is NT$46.74, compared to a current price of NT$43.70 — trading 6.5% below its estimated fair value. The current FCF Margin % is -22,689.17%. Senhwa Biosciences' overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Senhwa Biosciences (ROCO:6492), the current FCF Margin % is -22,689.17% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Senhwa Biosciences (ROCO:6492) Overvalued in 2026?

Based on GuruFocus' analysis, Senhwa Biosciences stock appears to be undervalued. The current stock price of NT$43.70 is trading 6.5% below its estimated GF Value™ of NT$46.74. GuruFocus considers Senhwa Biosciences to be Fairly Valued.

Key valuation signals for ROCO:6492:

  • FCF Margin %: -22,689.17%
  • GF Value™: NT$46.74 vs. price of NT$43.70 (6.5% below fair value)
  • GF Score™: 70/100 with 2 warning signs

No single metric tells the full story. See the ROCO:6492 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Senhwa Biosciences Business Description

Address Peihsin Road, 10th Floor, No. 225, Section 3, Hsintien District, New Taipei City, TWN, 23143
Senhwa Biosciences Inc is engaged in the development of new drugs and special pharmaceutical ingredients, focusing on human efficacy. The company's product pipeline includes Pidnarulex (CX-5461), being developed as a therapy for solid tumours, B-cell lymphoma, ovarian cancer, and other oncology indications; and Silmitasertib (CX-4945), being developed to counter neuroblastoma, medulloblastoma, basal cell carcinoma, and other indications. Geographically, the company generates all of its revenue from Taiwan.
70GF Score

Get the complete analysis for ROCO:6492

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$43.70
Price
NT$46.74
GF Value